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To study the  polymorphic variants in CYP2D6 and the C-174G promoter polymorphism of the IL-6 gene on S. haematobium infected patients from an endemic 
area of Guinea Bissau. 
BACKGROUND 
•Our group has shown that schistosome egg associated catechol estrogens induce tumor-like phenotypes in 
urothelial cells. These estrogen metabolites might also be the cause of schistosomiasis associated 
infertility (Botelho et al, Trends in Parasitol, 2015). 
•The cytochrome P450 (CYP) genes are oxygenases involved in estrogen biosynthesis and metabolism, 
generation of DNA damaging procarcinogens, and response to anti-estrogen therapies (Blackburn et al, 
Cancer Causes and Control, 2015). 
•IL6 Interleukin-6 (IL-6) is a pleiotropic cytokine expressed in many tissues. These cytokine is largely 
expressed in female urogenital tract as well as reproduction organs. Very high or very low levels of IL-6 
are associated with estrogen metabolism imbalance (Prins et al, J Reprod Immunol, 2012). 
Fig. 1: Schistosoma spp. life cycle. 
METHODOLOGICAL STRATEGY 
RESULTS 
1. We found that 25% of schistosomiasis haematobia infected patients are 
carriers of the inactivated allele CYP2D6*5 which is characterized by a 
deletion of the entire CYP2D6 gene. The frequency of this allele in a healthy 
population is 5% (Gaedigk et al, 1991). 
CONCLUSIONS 
2. DNA was extracted from urine sediments 
3. LightMix Kit for the detection of CYP 2D6 alleles *3, *4 and *5/*5 and 
LightMix Kit for the detection of IL 6 G-174C were used with LightCycler 
2.0 Instrument. 
1. 42 infected patients were targeted in this study.  
•1. This survey provides for the first time data on the frequency of inactivating alleles of CYP2D6 and IL6 G-174C polymorphisms in S. haematobium infected 
patients.   
•2. Allele CYP2D6*5 and IL6  -174C variant are associated with schistosomiasis haematobia infection and could explain schistosomiasis associated cancer and 
infertility. 
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Fig. 5: Patient sample melting peak for CYP2D6*5 deletion. 
2. In our study 6.25% of patients infected with S. haematobium 
have the IL6 -174C mutant where this variant is associated with 
lower IL6 secretion. The frequency of this variant in a healthy 
population is 0.4% (Fishman et al, J Clin Invest, 1998). 
 
Fig. 6: Patient sample melting peak for IL6 -174C mutant. 
Fig. 2: Catechol-estrogens produced by S. haematobium. 
 Fig.3: Control samples melting peak for CYP2D6*5 
deletion 
Fig. 4: Control sample melting peak for IL6 -174C 
mutant 
